Patents by Inventor Robert S. Lowe

Robert S. Lowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein delivery system using human papillomavirus virus-like particles
    Patent number: 6991795
    Abstract: Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: January 31, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Lowe, Kathrin U. Jansen, Joseph G. Joyce, William L. McClements, James C. Cook, III, Jessica Ching-Yee Ling, Michael P. Neeper
  • Production of chimeric human papillomavirus
    Patent number: 6841157
    Abstract: This invention relates to infectious chimeric papillomaviruses, and especially those where the early genes are from human papillomavirus (HPV) 18, and the late genes are from another HPV. Also presented are methods of culturing the virus in raft cell cultures, and to assays utilizing these chimeric viruses.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Lowe, Craig M. Meyers, Jiaping Zhang, Michelle Kaupas, Kathrin Ute Jansen
  • Production of chimeric human papillomavirus
    Publication number: 20040043471
    Abstract: This invention relates to infectious chimeric papillomaviruses, and especially those where the early genes are from human papillomavirus (HPV) 18, and the late genes are from another HPV. Also presented are methods of culturing the virus in raft cell cultures, and to assays utilizing these chimeric viruses.
    Type: Application
    Filed: July 28, 2003
    Publication date: March 4, 2004
    Inventors: Robert S. Lowe, Craig M. Meyers, Jiaping Zhang, Michelle Kaupas, Kathrin Ute Jansen
  • Varicella-zoster virus as a live recombinant vaccine
    Patent number: 5310668
    Abstract: A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Elliott Kieff, Edward M. Scolnick, Robert S. Lowe
  • DNA encoding immunogenic gpIII glycoprotein of varicella-zoster virus
    Patent number: 5306635
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: June 9, 1992
    Date of Patent: April 26, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Mark W. Riemen, Ronald W. Ellis, Andrew J. Davison, Robert S. Lowe
  • Vaccine against varicella-zoster virus
    Patent number: 4952674
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. Antibodies directed against peptides imputed from the DNA sequence can react with the glycoprotein, which itself is reactive with neutralizing antibodies. The amino-terminal sequence of the purified glycoprotein is identical to a portion of the amino acid sequence imputed from the DNA sequence. This glycoprotein is useful for the preparation of a vaccine against VZV.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: August 28, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Paul M. Keller, Ronald W. Ellis, Robert S. Lowe, Mark W. Riemen, Andrew J. Davison
  • Vaccine against varicella-zoster virus
    Patent number: 4812559
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human convalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
    Type: Grant
    Filed: March 23, 1987
    Date of Patent: March 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Paul M. Keller, Robert S. Lowe, Andrew J. Davison
  • Vaccine against varicella-zoster virus
    Patent number: 4686101
    Abstract: A gene of varicella-zoster virus (VZV) which encodes immunogenic outer surface viral proteins has been identified by DNA sequence analysis. This gene can hybrid select messenger RNA which encodes and expresses a protein which reacts with human canvalescent zoster sera and with polyclonal monospecific antisera which neutralize viral infectivity. These proteins are useful for the preparation of a vaccine for VZV.
    Type: Grant
    Filed: August 2, 1985
    Date of Patent: August 11, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Ronald W. Ellis, Robert S. Lowe, Paul M. Keller, Andrew J. Davison